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Background: Although carotid artery stenting (CAS) has been proposed as an 
alternative to carotid endarterectomy in cerebral revascularization, restenosis remains an 
unsolved issue. Cilostazol is a unique antiplatelet drug that has vasodilatory effects and 
inhibits smooth muscle cell proliferation. We investigated whether 
cilostazol reduces restenosis after CAS. 
Methods: A database of 113 consecutive CAS between April 2002 and December 2007 
was assessed retrospectively. All patients received aspirin (100mg/day) and another 
antiplatelet drug such as cilostazol (200mg/day), ticlopidine (200mg/day), or clopidogrel 
(75mg/day) at least 3 days before CAS. Two antiplatelet drugs were continued for 2 to 3 
months after CAS, and reduced to one thereafter. Patients were evaluated at 3 and 6 
months and at 6-month intervals thereafter with duplex 
ultrasonography (US). Angiography was used to confirm when stenosis was suspected 
as greater than 50% with US. 
Results: We were able to follow 97 patients over a 12 month period. The overall 
combined rate of stroke, myocardial infarction, and death was 3.1% at 30 days, and 4.1% at 1 
year. 11 patients (11%) had in-stent recurrent stenosis. Restenosis occurred within 12 
months of CAS in 10 patients (9.7%). In-stent restenosis was significantly reduced 
in the cilostazol (+) group (0% [0/27] vs. 15.7% [11/70], p= .03). Patient 
characteristics were similar between the cilostazol (+) and cilostazol (-) groups. 
Conclusions:  Although this study was retrospective and nonrandomized, the results suggest
 that cilostazol administration improves long-term patency after CAS 
due to its inhibitory effect on smooth muscle cell growth. 
Running Title: Cilostazol reduces restenosis after CAS 
Key words: Carotid artery stenting, Cilostazol, In-stent restenosis. 
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 Carotid artery stenting (CAS) is being used widely to treat severe carotid obstructive disease, 
and it is now accepted as a less invasive technique that provides an alternative for 
some patients, particularly those with significant comorbidities.1-5 Although distal 
embolism decreased with use of the embolization protection device (EPD), up to 10% 
of patients develop > 50% stenosis as determined by angiography or carotid duplex 
ultrasound (US) scanning and this problem is not yet solved.3, 6-8 In some patient subgroup, 
such as women and the elderly, it approaches 20%.7 
 These series of studies placed aspirin, ticlopidine or clopidogrel as the current standard of 
antiplatelet drugs. Cilostazol, a cyclic 
adenosine monophosphate phosphodiesterase inhibitor, has multiple actions including vasodil
ation and inhibition of platelet aggregation.9-11 Cilostazol is widely used as an antiplatelet 
drug in Japan. Several small trials reported that cilostazol use after endovascular treatment 
with peripheral artery and coronary artery diseases has a low rate of 
in-stent restenosis.12-22 However, it is not known whether a preventive effect of cilostazol 
on restenosis is similarly recognized after CAS. Accordingly, the present 
study was undertaken to determine whether cilostazol 
is effective in preventing restenosis after CAS compared to other antiplatelet drugs. 
 
METHODS 
 Study design and patient sample. 
A retrospective study was conducted of patients who had undergone CAS between April 
2002 and December 2007. Carotid duplex US scannings were performed 
before the stenting procedure, and high grade carotid stenosis was documented in 
all patients. High-risk patients for CEA with symptomatic carotid stenosis of 50% or greater 
and asymptomatic carotid stenosis of 80% or greater were considered for the stenting protocol. 
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Procedural indications, clinical, laboratory, antiplatelet drugs, techniques, treatment outcomes, 
and postoperative course were analyzed. 
 Eligibility for CAS was further determined on the basis of criteria established at a 
consensus conference,23 including recurrent stenosis after previous CEA; contralateral carotid 
occlusion; primary lesions in patients with significant medical comorbid conditions, such 
as coronary artery disease requiring angioplasty or bypass grafting that has not or cannot 
be revascularized, history of congestive heart failure, current ejection fraction 30% 
or less (stage III or IV of the New York Heart Association classification), steroid-dependent 
chronic obstructive pulmonary disease, or measured 1-second forced expiratory volume 30% 
or less; primary lesion anatomically inaccessible at surgery such as high carotid bifurcation 
(higher than the C2 level); and primary lesion with previous ipsilateral 
cervical radiation therapy. 
 Carotid artery stenting procedures (n=113) were performed in 106 patients over this period. 
We were able to follow 97 patients over 12 months. These included 83 men and 14 women 
with the mean age being 69.9±7.2 years. 61 patients (62.9%) had symptomatic stenosis; 
36 patients (37.1%) had asymptomatic lesions. Indications for carotid 
artery stenting included recurrent stenosis after previous CEA (n=5, 5.1%), high-risk cardiac 
comobidity (n=26, 26.8%), high-risk pulmonary comobidity (n=1, 1.0%), high carotid 
bifurcation (n=30, 30.9%) and previous ipsilateral cervical radiation therapy (n=8, 
8.2%). Clinical characteristics are presented in Table 1. 
Carotid artery stenting protocol. 
All patients were examined prior to each procedure to ascertain neurological function 
by independent neurologist; duplex US scanning was also performed in all cases. 
Patients treated electively received aspirin (100mg/d) and another antiplatelet agent such 
as clopidogrel (75mg/d), ticlopidine (200mg/d), or cilostazol (200mg/d) for at least 3 
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days before the intervention. Patients electively received aspirin, 
and thienopyridine (ticlopidine or clopidogrel). In Japan, because Clopidogrel was approved 
by the pharmaceutical affairs from December, 2006, patients received ticlopidine before then, 
and clopidogrel was added since December 2006. In cases of the patients with peripheral 
artery disease or coronary artery disease, cilostazol and/or thienopyridine was added 
before carotid artery stenting. This combination of antiplatelet 
drugs was continued from the formula of the cardiovascular medicine. Standard 
monitoring techniques were employed, including intra-arterial pressure monitoring, oximetry, 
and continuous electrocardiography. During the procedure, the patient’s neurological 
status was continuously monitored via verbal command. 
 Standard retrograde access was achieved in the common femoral artery under local 
anesthesia with 1% lidocaine. An 8F vascular sheath was inserted. Heparin 
was administered to achieve an activated clotting time of over 300 seconds. An 8F 
guiding catheter was navigated into the common carotid artery. Carotid angiogram and 
intracranial injections were performed. A 0.018-inch guidewire system with EPD was then 
manipulated to cross the internal 
carotid lesion. For the patients with high-grade stenosis which was nearly occluded or 
with thrombosis, procedures were performed 
using the reversed-flow system. After the activation of the embolic system, a coaxial 
angioplasty balloon was used to predilate the carotid lesion if necessary. Next, a 
self-expanding carotid stent was deployed across the internal carotid stenosis. Post-dilatation 
was performed if necessary. On completion, ipsilateral cervical and intracranial carotid 
angiography was performed to assess technical success and to exclude distal cerebral 
embolization. 
 Patients were monitored in an intensive care unit overnight after the procedure, and 
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were discharged 3 or 4 days after the procedure. Postprocedure clinical examination and 
duplex US scanning were performed before discharge, to confirm stent patency and position. 
One antiplatelet drug was prescribed to be taken for life and another one to be terminated after 
2 or 3 months. Aspirin was prescribed to be taken for life basically. In 
cases of the patients with peripheral artery disease or coronary artery disease, cilostazol 
and/or thienopyridine was added before carotid artery stenting. This combination of 
antiplatelet drugs was continued from the formula of the cardiovascular 
medicine. After CAS, this combination was continued for life. 
 Follow-up protocol and criteria for restenosis assessment. 
 All patients were followed at the hospital’s outpatient clinic at 1, 3, 6, 9 and 12 
months after the procedure and every 6 
months thereafter. During these routine postoperative visits, the surgeon and 
independent neurologist examined each patient, and carotid duplex US scans were performed 
at 3 and 6 months and at 6-month intervals thereafter. The velocity criteria 
used to evaluate carotid artery stenosis were modifications of the Japanese Academy of 
Neurosonology Guidelines for Neurosonology and were validated in our hospital. 
Peak systolic velocity greater than 150 cm/s correlated with greater than 50% 
stenosis.24 Additionally, luminal reductions on grayscale images and 
color flow disturbances were further evaluated. In-stent restenosis, identified by US scanning, 
was further verified by carotid angiography, and stenosis was measured 
geometrically on the basis of the North American Symptomatic Carotid Endarterectomy Trial 
(NASCET) criteria.25 When more than 50% restenosis was recognized, carotid 
angioplasty and possible stenting were subsequently performed. 
 Statistical analysis. 
 Clinical variables that may be associated with restenosis after CAS were analyzed. Data 
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are shown as mean ± standard deviation (SD). The unpaired t-test 
was used to compare continuous variables between the groups. The chi-square test 
or Fisher’s exact test was used to compare ratios. Statistical significance was defined as a p< 
0.05. 
 
RESULTS 
 Thir ty-day and one-year  outcome of carotid ar tery stenting.  
The lesion was accessed and the procedure performed successfully in all cases, for a technical 
success rate of 100%. Mean stenosis treated was 82.9±9.5%, and post-treatment 
mean residual stenosis was 5.2±0.5%. Wallstents (Boston Scientific, Natick MA, USA) 
were deployed in 71 procedures (73.2%), Precise (Cordis, Miami FL, USA) in 
8 procedures (8.2%), Protage (eV3, Plymouth, Minn, USA) in 2 procedures (2.1%), Xpert 
(Abbott Vascular, Redwood City, Calif, USA) in 1 procedure (1.0%), and SMARTeR stent 
(Cordis) in 15 procedures (15.5%). All stenting procedures were performed by using EPD, 
including the PercuSurge Guardwire device (Medtronic, Minneapolis MN, USA; n=82; 
84.5%), AngioGuard XP (Cordis; n=7; 7.2%), and reversed-flow system (n=7; 7.2%). 
Overall 30-day stroke, myocardial infarction, and death rate was 3.1% (n=3). Each 
of the three strokes was minor (two ipsilateral minor strokes and one contralateral stroke). 
Post operative duplex US scanning was performed within a 
week after CAS. There were no in-stent restenosis, carotid dissections, or thromboses in 
all patients. During one-year follow-up, myocardial infarction was noted in one patient. Over 
all one-year outcome for stroke, myocardial infarction, and death was 4.1%. 
 Long-term follow-up and in-stent restenosis. 
 During follow-up of 12 to 67 months (mean, 28.6±13.3 months), 9 patients were lost 
in the follow-up. In-stent restenosis confirmed by duplex US scanning and 
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angiography was detected in 11 (11.3%) of 97 carotid arteries.  Recurrent stenosis occurred 
within 5 to 16 months (mean, 8.9±3.0 months). Mean restenosis was 55.5%±7.2%, and 
mean peak systolic velocity was 200.8±75.1 cm/s. None of the patients showed 
symptoms of recurrent stenosis. There were ten men and one woman with mean an age of 
69.3±16.2 years. In comparing patient characteristics, clinical symptoms, CAS 
indications, CAS devices, and CAS technique between the patients with 
in-stent restenosis and without in-stent restenosis, no significant difference was noted 
(Table 2).  
 Two patients did not want re-treatment and were followed up with serial clinical evaluation 
and duplex US scanning at 3-month to 6-month intervals. Nine of eleven patients underwent 
endovascular repeat intervention; five of which were repeat balloon angioplasty with four 
being repeat angioplasty and secondary stenting. Technical successes were achieved in 
all patients, and the mean carotid artery stenosis decreased from 54.6% to 11% 
after reintervention. No procedural related complications were noted after 
in-stent restenosis intervention. All patients who underwent reintervention have remained rec
urrence-free during follow-up periods (20.6 month median). 
  
 Post-CAS antiplatelet therapy and in-stent restenosis. 
 Antiplatelet drugs that were continued for 1-year after CAS are presented 
in table 3. The combinations of antiplatelet 
agents were as follows (aspirin n=28, ticlopidine n=3, clopidogrel n=10, cilostazol n=1, 
aspirin + ticlopidine n=23, aspirin + clopidogrel n=6, aspirin + cilostazol n=19, cilostazol + 
clopidogrel n=3, aspirin + ticlopidine + cilostazol n=1, aspirin + clopidogrel + cilostazol n=3). 
No significant differences were noted in overall 30-day and 1-year stroke, myocardial 
infarction, and death among each drug group. Among the cilostazol (+) 
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group, there were significantly fewer incidences of restenosis compared to patients without 
cilostazol (0% vs. 15.7%, p= .03). The restenosis rate was significantly higher 
in patients who took ticlopidine compared to patients without ticlopidine (25.9% vs. 
5.7%, p= .01). Patient, lesion characteristics, and CAS technique did not differ 
between the cilostazol (+) and cilostazol (-) groups. Use of additional drugs was similar 
between the groups, except that ticlopidine was used more frequently in the cilostazol (-) 
group than in the cilostazol (+) group. 
DISCUSSION 
 The incidence of postprocedural in-stent restenosis ranges from 1% to 50% 
in published reports.1, 3, 26-28 The reported rate of in-stent restenosis depends on the definition 
of recurrent stenosis, duration of follow-up, and the methods of diagnosis. Although most 
of these reports were based on short follow-up periods, several 
authors more recently presented findings after periods of longer follow-up. Setacci et 
al29 reported a 3.6% incidence of high-grade restenosis (> 80%) over a 21 
month follow-up period with more than 372 carotid stents. Similarly, Chakhtoura et 
al26 reported an 8% high-grade restenosis rate during their 18 month follow-up of 50 carotid 
stent procedures. Our study, likewise, demonstrated an 11.3% moderate-grade (> 50%) 
in-stent restenosis rate during a mean 28.6 month follow-up period. 
 Cilostazol, a phosphodiesterase 3 inhibitor has antiplatelet action 
and vasodilatory effects and inhibits smooth muscle cell proliferation.10, 11, 31, 
32 It has been reported that cilostazol increases the cyclic 
adenosine monophosphate phosphodiesterase level in vascular smooth 
muscle cells, resulting in upregulation of the antioncogenes p53 and p21 
and hepatocyte growth factor.33 Because the increase in p53 protein blocks cell 
cycle progression and induces apoptosis in vascular smooth 
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muscle cells, these mechanisms have an 
antiproliferative effect .34 Furthermore, hepatocyte growth factor stimulates re-endothelization 
after vascular injury, inhibits abnormal vascular smooth muscle cell growth, and 
improves endothelial function.35 Because one of the major causes of recurrent 
stenosis after CAS 
is neointimal hyperplasia, these actions may possibly explain the beneficial effect of 
cilostazol on reducing the in-stent restenosis rate. Cilostazol 
also inhibits P-selectin-mediated leukocyte activation, platelet-leukocyte interaction, and 
subsequent Mac-I-mediated leukocyte activation.36 Because inhibition 
of these actions is thought to reduce neointimal thickening after vascular 
injury, this mechanism may be also be important in the reduction of restenosis after CAS. 
 Earlier studies have indicated that cilostazol improves symptoms and 
increases walking distance in patients with peripheral artery disease with intermittent 
claudication.12 Recently, studies have shown that 
cilostazol reduces restenosis and target lesion revascularization 
after percutaneous transluminal angioplasty in patients with peripheral 
artery disease.13-15 Consequently, cilostazol is a class 1 drug for patients with peripheral 
artery disease according to American Heart Association guidelines.37 Furthermore, several 
studies have shown that cilostazol has the potential to reduce restenosis compared with aspirin 
after balloon angioplasty, stent implantation, and directional 
coronary atherectomy.16-20 Douglas JS et al12 reported that cilostazol 
was effective on restenosis after coronary artery stenting when 
compared to placebo-treated patients. Tanabe et al21 reported on cilostazol’s effect 
on restenosis after coronary angioplasty and stenting in 
comparison to coronary artery stenting with ticlopidine.  
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In the study presented here, cilostazol was as effective as other antiplatelet 
drugs in preventing periprocedual and 1-year complications after CAS, as evidenced 
by the lack of any significant differences in vascular events observed at the 30-day and 
1-year follow-ups. Furthermore, cilostazol showed 
more effectiveness in reducing restenosis after stent implantation than the other antiplatelet 
drugs. The inhibitory effect of cilostazol on restenosis may not be due to its antiplatelet 
effects but is possibly due to its direct inhibition of smooth muscle cell growth. 
 This study was a nonrandomized, retrospective at a single center trial, 
and there were few numbers. A large-scale, prospective, multicenter study should 
be undertaken to verify these preliminary conclusion. 
 
CONCLUSION 
Cilostazol may have the potential to reduce the rate of restenosis after CAS 
due to its inhibitory effect on smooth muscle cell growth. 
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Table 1: Patient characteristics 
 
       Total (n=97)      
Age (y) (mean ± SD)     69.6±7.2 
Male sex, n (%)      83 (85.6) 
Type of lesion 
 Asymptomatic carotid stenosis, n (%)  36 (37.1) 
 Symptomatic carotid stenosis, n (%)  61 (62.9) 
  Stroke, n (%)    38 (39.2) 
  Transient ischemic attack, n (%)  16 (16.5) 
  Amaurosis fugax, n (%)   7 (7.2) 
 Severity of stenosis (%) (mean ± SD)  82.9±9.5 
Comorbidities 
 Coronary artery disease, n (%)   32 (33.0) 
 History of myocardial infarction, n (%)  18 (18.6) 
 Smoking, n (%)     70 (72.2) 
 Hypertension, n (%)    78 (80.4) 
 Diabetes, n (%)     29 (29.9) 
Chronic obstructive pulmonary disease, n (%) 1 (1.0) 
Hypercholesterolemia, n (%)   49 (50.5) 
Renal insufficiency, n (%)   7 (7.2) 
Peripheral artery disease, n (%)   8 (8.2) 
CAS indications 
 High-risk cardiac comobidity, n (%)  26 (26.8) 
 High carotid bifurcation, n (%)   30 (30.9) 
High-risk pulmonary comobidity, n (%)  1 (1.0) 
 History of neck irradiation, n (%)   8 (8.2) 
 Post CEA stenosis, n (%)    5 (5.1) 
 
CAS, carotid artery stenting; CEA, carotid endarterectomy. 
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Table 2: Comparison of patient characteristics, clinical symptoms, CAS indications, CAS 
devices, and CAS technique between the patients with in-stent restenosis and without 
in-stent restenosis. 
      No   ISR 
             ISR       (≧50%)     P value 
            (n=86)        (n=11) 
Age (y) (mean ± SD)        69.7±7.2      69.3±7.9       NS 
Male sex (%)     84.8  90.1       NS 
Type of lesion 
 Asymptomatic carotid stenosis (%)  38.4  27.3       NS 
 Symptomatic carotid stenosis  (%)  61.6  72.7       NS 
  Stroke (%)   38.4  45.5       NS 
  Transient ischemic attack (%)  16.2  18.1       NS 
  Amaurosis fugax (%)  7.0  9.1    NS 
 Severity of stenosis (%) (mean ± SD)      82.5±9.9      85.8±5.2       NS 
Comorbidities 
 Coronary artery disease (%)   32.5  36.4       NS 
 History of myocardial infarction (%)  18.6  18.2       NS 
 Smoking (%)    70.9  81.8       NS 
 Hypertension (%)    82.6  63.6       NS 
 Diabetes (%)    30.2  27.3       NS 
Chronic obstructive pulmonary disease (%) 1.2  0       NS 
Hypercholesterolemia (%)   51.2  45.5       NS 
Renal insufficiency (%)   8.1  0       NS 
Peripheral artery disease (%)   8.1  9.1       NS 
CAS indications 
 High-risk cardiac comobidity (%)  26.7  27.3       NS 
 High carotid bifurcation (%)   30.2  36.4       NS 
High-risk pulmonary comobidity (%)  1.2  0       NS 
 History of neck irradiation   8.1  9.1       NS 
 Post CEA stenosis    5.8  0       NS 
Stents 
 Wallstent (%)    74.4  63.6       NS 
 Precise (%)    8.1  9.1       NS 
 SMARTeR (%)    14.0  27.2       NS 
 Xpert (%)    1.2  0       NS 
 Protage (%)    2.3  0       NS 
EPD 
 PercuSurge Guardwire device (%)  83.7  90.9       NS 
 AngioGuard (%)    7.0  9.1       NS 
 Navi balloon (%)    1.2  0       NS 
 Reversed-flow system (%)   8.1  0       NS 
 
Pre-balloon dilatation (%)    97.7  100       NS 
Post-balloon dilatation (%)    80.2  72.7       NS 
 
Post-treatment residual stenosis (%) (mean ± SD)        4.8±5.2        8.9±8.0       NS 
 
ISR, in-stent restenosis; CAS, carotid artery stenting; NS, not significant; CEA, carotid 
endarterectomy, EPD; embolization protection device 
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Table 3. Antiplatelet drugs used in 97 patients after CAS for a year. 
 
    N  Overall 30-day stroke,   Overall 1-year stroke, 
myocardial infarction, and death   myocardial infarction, and death       restenosis 
          (n=3)    (n=4)    (n=11) 
Aspirin (+)   80   2 (2.5%)   3 (3.8%)   8 (10.0%) 
Aspirin (-)   17   1 (5.9%)   1 (5.9%)   3 (17.6%) 
Cilostazol (+)   27   1 (3.7%)   1 (3.7%)   0 (0%) * 
Cilostazol (-)   70   2 (2.9%)   3 (4.3%)   11 (15.7%) 
Ticlopidine (+)   27   0 (0%)    1 (3.7%)   7 (25.9%) ** 
Ticlopidine (-)   70   3 (4.3%)   3 (4.3%)   4 (5.7%) 
Clopidogrel (+)   22   2 (9.1%)   2 (9.1%)   3 (13.6%) 
Clopidogrel (-)   75   1 (1.3%)   2 (2.7%)   8 (10.7%) 
 
              *p= .03; **p= .01 
 
